Method for treating diseases
Patent Information
- Application Number
- HK62026123379
- Authority / Receiving Office
- HK · HK
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-07-07
- Filing Date
- 2026-05-14
- Publication Date
- 2026-07-31
Smart Images
Figure 00000000_0000_ABST
Abstract
Description
Summary of Methods for Treating Diseases In one embodiment of the present invention, the present invention relates to a pharmaceutical composition for treating an individual suffering from a disease selected from communication disorders, motor impairments, cognitive impairments, mental disorders, sensory disorders, autism spectrum disorders, and pervasive developmental disorders, wherein the pharmaceutical composition comprises L-serine or a pharmaceutically acceptable salt thereof.
Claims
1. A pharmaceutical composition for treating an individual having a disease selected from communication disorder, abnormal motor ability, cognitive disorder, mental disorder, sensory disturbance, autism spectrum disorder, and pervasive developmental disorder, wherein the pharmaceutical composition comprises L-serine or a pharmaceutically acceptable salt thereof.
2. The pharmaceutical composition according to Claim 1, wherein the autism spectrum disorder is childhood autism.
3. The pharmaceutical composition according to Claim 1 or 2, wherein the L-serine or the pharmaceutically acceptable salt thereof is administered twice a day to the individual.
4. The pharmaceutical composition according to any one of Claims 1 to 3, wherein the pharmaceutical composition is a formulation for oral administration.
5. The pharmaceutical composition according to any one of Claims 1 to 4, wherein the pharmaceutical composition is a syrup formulation.
6. The pharmaceutical composition according to any one of Claims 1 to 5, wherein the individual is 18 years old or younger.
7. The pharmaceutical composition according to any one of Claims 1 to 6, wherein the individual is 13 years old or younger, 11 years old or younger, 7 years old or younger, less than 7 years old, 2 years old to 7 years old, or 2 years old to 6 years old.
8. The pharmaceutical composition according to any one of Claims 1 to 7, wherein a body weight of the individual is 10 to 100 kg.
9. The pharmaceutical composition according to any one of Claims 1 to 8, wherein a body weight of the individual is 10 to 60 kg.
10. The pharmaceutical composition according to any one of Claims 1 to 9, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 1 g to 60 g.
11. The pharmaceutical composition according to any one of Claims 1 to 10, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 2 g to 30 g or 2 g to 28 g.
12. The pharmaceutical composition according to any one of Claims 1 to 10, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 2 g to 15 g or 2 g to 14 g.
13. The pharmaceutical composition according to any one of Claims 1 to 10, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 4 g to 30 g or 4 g to 28 g.
14. The pharmaceutical composition according to any one of Claims 1 to 13, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 100 mg / kg to 600 mg / kg.
15. The pharmaceutical composition according to Claim 14, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 140 mg / kg to 580 mg / kg or 140 mg / kg to 572 mg / kg.
16. The pharmaceutical composition according to any one of Claims 1 to 13, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 200 mg / kg to 400 mg / kg, 280 mg / kg to 580 mg / kg, or 280 mg / kg to 572 mg / kg.
17. The pharmaceutical composition according to any one of Claims 1 to 14, wherein a single administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 70 mg / kg to 280 mg / kg, 140 mg / kg to 290 mg / kg, or 140 mg / kg to 286 mg / kg.
18. The pharmaceutical composition according to any one of Claims 1 to 17, further comprising one or more among a sweetener, a thickener, a pH adjusting agent, a preservative, and a solvent.
19. A method for treating a disease selected from communication disorder, abnormal motor ability, cognitive disorder, mental disorder, sensory disturbance, autism spectrum disorder, and pervasive developmental disorder, wherein the method comprises a step of administering L-serine or a pharmaceutically acceptable salt thereof to an individual having the disease.
20. The method for treating a disease according to Claim 19, wherein the autism spectrum disorder is childhood autism.
21. The method for treating a disease according to Claim 19 or 20, wherein the L-serine or the pharmaceutically acceptable salt thereof is administered twice a day to the individual.
22. The method for treating a disease according to any one of Claims 19 to 21, wherein the L-serine or the pharmaceutically acceptable salt thereof is orally administered to the individual.
23. The method for treating a disease according to any one of Claims 19 to 22, wherein the L-serine or the pharmaceutically acceptable salt thereof is administered to the individual as a syrup formulation.
24. The method for treating a disease according to any one of Claims 19 to 23, wherein the individual is 18 years old or younger.
25. The method for treating a disease according to any one of Claims 19 to 24, wherein the individual is 13 years old or younger, 11 years old or younger, 7 years old or younger, less than 7 years old, 2 years old to 7 years old, or 2 years old to 6 years old.
26. The method for treating a disease according to any one of Claims 19 to 25, wherein a body weight of the individual is 10 to 100 kg.
27. The method for treating a disease according to any one of Claims 19 to 26, wherein a body weight of the individual is 10 to 60 kg.
28. The method for treating a disease according to any one of Claims 19 to 27, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 1 g to 60 g.
29. The method for treating a disease according to any one of Claims 19 to 28, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 2 g to 30 g or 2 g to 28 g.
30. The method for treating a disease according to any one of Claims 19 to 28, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 2 g to 15 g or 2 g to 14 g.
31. The method for treating a disease according to any one of Claims 19 to 28, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 4 g to 30 g or 4 g to 28 g.
32. The method for treating a disease according to any one of Claims 19 to 31, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 100 mg / kg to 600 mg / kg.
33. The method for treating a disease according to Claim 32, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 140 mg / kg to 580 mg / kg or 140 mg / kg to 572 mg / kg.
34. The method for treating a disease according to any one of Claims 19 to 31, wherein a total daily administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 200 mg / kg to 400 mg / kg, 280 mg / kg to 580 mg / kg, or 280 mg / kg to 572 mg / kg.
35. The method for treating a disease according to any one of Claims 19 to 31, wherein a single administration dosage of the L-serine or the pharmaceutically acceptable salt thereof is 70 mg / kg to 280 mg / kg, 140 mg / kg to 290 mg / kg, or 140 mg / kg to 286 mg / kg.
36. Use of the pharmaceutical composition according to any one of Claims 1 to 18 for manufacturing a medicament for ameliorating, preventing, or treating a disease selected from communication disorder, abnormal motor ability, cognitive disorder, mental disorder, sensory disturbance, autism spectrum disorder, and pervasive developmental disorder.